Canadian Technology Stocks
To say it has been a bumpy road for MediPattern (TSXV:MKI) investors of late might be an understatement. The Toronto based company, which designs medical imaging software, went public in 2005 then soared to $1.64 in the first days of 2008 on the promise of a new medical imaging system for breast cancer detection. But [...]
Last year, Canada became the first country to place an outright ban on bisephenol A, a toxic substance better know as BPA. Canada joined the European Union, which had, owing to BPA’s link to a range of neurological and thyroid issues, banned its use in plastic baby bottles. The scare, which was based on a [...]
To date, Vancouver’s Burcon Nutrascience has not produced revenue, yet the company commands a market cap of nearly $300 million. The reason? Burcon has already become a world leader in a space that seems to have few limits to its size. Burcon owns 127 patents around the extraction and purification of protein from plants. Many [...]
Everywhere you look, food is news. From the government of Algeria increasing wheat supplies after food riots, to food price inflation in India deterring foreign investors to the suicide of a Tunisian fruit seller sparking a revolution. When you can offer tangible improvements to a business that might be the most important on the planet, [...]
Shareholders of Laval, Quebec’s Labopharm (TSX:DDS) have had a tough few years. Shares of the pharmaceutical company, which specializes in control-release technologies, soared to over (US) $9 in 2006 as the company entered the once daily tramadol market. Tramadol is opioid analgesic, and is used in treating moderate to severe pain. The drug was developed [...]
The prospect of losing their NASDAQ listing has hung over Angiotech Pharmaceuticals for a long time. Shares of the once high-flying Vancouver medical device company have been slipping for years, from a meteoric high of $36.95 on February 6th, 2004 to mere pennies today. While the delisting, which will happen on January 13th, was a [...]
Early this year, things weren’t looking that great for Quebec City’s AEterna Zentaris (TSX:AEZ). On January 21st, the company received notification from the NASDAQ that they didn’t comply with the exchange’s minimum bid price requirements. Shares of AEterna, an oncology and endocrine therapy drug development company with a Phase 3 cancer therapy candidate, Perifosine, had [...]
It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers have contributed to The Human Genome project, cracked the genetic code of the mosquito that carries the deadliest strain of malaria, and deciphered human chromosome 7, which holds the gene for cystic fibrosis. Our December issue is about Canadian Life Sciences stocks carrying the torch of innovation.
It’s been nearly a century since Canada’s greatest achievement in biotech took place; the discovery of insulin by Frederick Banting and his assistant Charles Best, in 1922. While nothing since has matched that miraculous feat, which has saved countless millions of lives, it’s not like Canada has been sitting still in the meantime. Canadian researchers [...]
Calgary’s Oncolytics Biotech grew out of discoveries made in the 1990′s in the Department of Microbiology and Infectious Diseases at the University of Calgary. The Company’s Reolysin, a formulation of reovirus, a family of viruses that can affect the gastrointestinal system and have shown to have oncolytic, or cancer killing properties, is about to enter [...]
